<DOC>
	<DOCNO>NCT02599324</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , efficacy combination treatment ibrutinib everolimus , paclitaxel , docetaxel , cetuximab select advanced gastrointestinal genitourinary tumor .</brief_summary>
	<brief_title>A Study Evaluate Ibrutinib Combination Therapy Patients With Selected Gastrointestinal Genitourinary Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>RCC ( clear cell ) , urothelial carcinoma ( transitional cell ) , gastric gastroesophageal junctional ( GEJ ) adenocarcinoma , KRAS NRAS wildtype EGFR express CRC For RCC : previously receive least 1 4 line therapy , one therapy must include VEGF TKI ECOG performance status 01 ( score 2 may acceptable ) For urothelial carcinoma : previously receive least 1 2 line therapy , one therapy must include platinum base regimen ECOG performance status 01 For gastric GEJ adenocarcinoma : previously receive least 1 3 line therapy , one therapy must include fluoropyrimidine base regimen ECOG performance status 01 For CRC : previously receive least 2 4 line therapy , must include irinotecan oxaliplatin base regimen ECOG performance status 01 ( score 2 may acceptable ) For cohort : Adequate hematologic function : Absolute neutrophil count ( ANC ) &gt; 1500 cells/mm3 For RCC , platelet count ≥80,000 cells/mm3 For urothelial carcinoma , gastric GEJ adenocarcinoma , CRC , platelet count ≥100,000 cells/mm3 For RCC , urothelial carcinoma , gastric GEJ adenocarcinoma , hemoglobin ≥8.0 g/dL For CRC , hemoglobin ≥9.0 g/dL Adequate hepatic renal function define : AST and/or ALT ≤5.0 x upper limit normal ( ULN ) liver metastasis , ≤3 x ULN without liver metastasis Alkaline phosphatase &lt; 3.0 x ULN ≤5.0 x ULN liver bone metastasis present Bilirubin ≤1.5 x ULN ( unless bilirubin rise due Gilbert 's syndrome nonhepatic origin , hemolysis ) Estimated Creatinine Clearance ≥30 mL/min For RCC , prior treatment everolimus temsirolimus For urothelial carcinoma , prior treatment taxane For gastric GEJ adenocarcinoma , prior treatment taxane For CRC , prior treatment cetuximab panitumumab For cohort : concomitant use warfarin Vitamin K antagonists history stroke intracranial hemorrhage within 6 month prior enrollment major surgery within 4 week first dose study drug require treatment strong CYP3A inhibitor know bleed disorder hemophilia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>